Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity

Clinical Immunology and Immunopathology

Volumn 47, Issue 2, 1988, Pages 121-141

  Tan, Eng M ^a   Chan, Edward K L ^a   Sullivan, Kevin F ^a   Rubin, Robert L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY;

ADULT; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; MALE; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; AUTOIMMUNE DISEASES; CELL NUCLEUS; CONNECTIVE TISSUE DISEASES; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROCAINAMIDE; SCLERODERMA, SYSTEMIC; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023952345     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1016/0090-1229(88)90066-9     Document Type: Review

References (116)

1. Autoantibodies to nuclear antigens (ANA): Their immunobiology and medicine
2. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus
3. Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera
4. Differentiation of antinuclear antibodies giving speckled staining patterns in immunofluorescence
5. Mixed connective tissue disease—An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)
6. Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus
7. SnRNAs, SnRNPs, and RNA processing
8. snRNPs and scRNPs in eukaryotic cells
9. Splicing of Xenopus laevis ribosomal protein RNAs is inhibited in vivo by antisera to ribonucleoproteins containing U1 small nuclear RNA
10. Splicing pathways of SV40 in X. laevis oocytes differ in their requirements for snRNPs
11. Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma
12. Primary and secondary structure of U8 small nuclear RNA
13. Two novel classes of small ribonucleoproteins detected by antibodies associated with lupus erythematosus
14. Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: Further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells
15. Precursor molecules of both human 5S ribosomal and transfer RNAs are found by a cellular protein reactive with anti-La lupus antibodies
16. Identification of a La protein binding site in a RNA polymerase III transcript (4.51 RNA)
17. Autoantibody to a nuclear antigen in proliferating cells
18. A nuclear antigen associated with cell proliferation and blast transformation. Its distribution in synchronized cells
19. Identity of the proliferating cell nuclear antigen and cyclin
20. Autoantibody to centromere (kinetochore) in scleroderma sera
21. Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma
22. Isolation and analysis of cDNA clones expressing human lupus La antigen
23. cDNA cloning of a human autoimmune nuclear ribonucleoprotein antigen
24. Cloning of the human cDNA for the U1 RNA-associated 70K protein
25. Analysis of a cDNA clone expressing a human autoimmune antigen: Full-length sequence of the U2 small nuclear RNA-associated B′ antigen
26. Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen
27. Molecular cloning of cDNA coding for rat proliferating cell nuclear antigen (PCNA)/cyclin
28. DNA and antibody to DNA in the serum of patients with systemic lupus erythematosus
29. Antibodies to DNA
30. The antigenic determinants of denatured DNA reactive with lupus erythematosus serum
31. Antibodies to histones in drug-induced and idiopathic lupus erythematosus
32. Multiple autoantibodies in cell constituents in systemic lupus erythematosus
33. Specificity of anti-histone antibodies in systemic lupus erythematosus
34. Protein antigens of the RNA-protein complexes detected by anti-Sm and anti-RNP antibodies found in serum of patients with systemic lupus erythematosus and related disorders
35. Synthesis and assembly of human small nuclear ribonucleoproteins generated by cell-free translation
36. Molecular properties of the Ro/SSA antigen and enzyme-linked immunosorbent assay for quantitation of antibody
37. The importance of tissue substrate in the SS-A/Ro antigen-antibody system
38. Identification of the SS-A/Ro intracellular antigen with autoimmune sera
39. Differentiation and characterization of autoantibodies and their antigens in Sjogren's syndrome
40. Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus
41. Interaction between VA-RNA and the lupus antigen La: Formation of a ribonucleoprotein particle in vitro
42. Epitopes, structural domains and assymmetry of amino acid residues in SS-B/La nuclear protein
43. The small nuclear ribonucleoprotein SS-B/La binds RNA with a conserved protease-resistant domain of 28 KD
44. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap
45. Identification of Ki (Ku, p70/p80) autoantigens and analysis of anti-Ki autoantibody reactivity
46. Use of monoclonal antibodies for the characterization of novel DNA-binding proteins recognized by human autoimmune sera
47. Mechanisms of interaction between Ku protein and DNA
48. Lupus autoantibodies target ribosomal P proteins
49. Identification of ribosomal protein autoantigens
50. Characterization of proliferating cell nuclear antigen recognized by autoantibodies on lupus sera
51. Purification and N-terminal amino acid sequence of proliferating cell nuclear antigen (PCNA)/cyclin and development of ELISA for anti-PCNA antibodies
52. Proliferating cell nuclear antigen in blast crisis cells of patients with chronic myeloid leukemia
53. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle
54. Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication
55. Alu RNA-protein complexes formed in vitro react with a novel lupus autoantibody
56. Profiles of antinuclear antibodies in systemic rheumatic diseases
57. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus
58. Are snRNPs involved in splicing?
59. A mechanism for RNA splicing
60. A small nuclear ribonucleoprotein is required for splicing of adenoviral early RNA sequences
61. Splicing of messenger RNA precursors
62. The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro
63. Cyclin/PCNA is the auxiliary protein of DNA polymerase delta
64. Functional identity of proliferating cell nuclear antigen and a DNA polymerase delta auxiliary protein
65. Drug-induced lupus erythematosus
66. Anti-DNA antibody in procainamide-induced lupus erythematosus
67. Procainamide elicits a selective autoantibody immune response
68. IgG antibodies to the histone complex H2A-H2B characterize procainamide-induced lupus
69. Antibodies from patients with drug-induced and idiopathic lupus erythematosus react with epitopes restricted to the amino and carboxyl termini of histones
70. Anti-histone antibodies in idiopathic and drug-induced lupus recognize distinct intrahistone regions
71. Antihistone antibodies
72. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome
73. Serologic changes during induction of lupus-like disease by procainamide
74. Antibodies against distinct nuclear matric proteins are characteristic of mixed connective tissue disease
75. Genetics, hypersensitivity and the connective tissue diseases
76. Preliminary diagnostic criteria for classification of mixed connective tissue disease
77. Rheumatic disease syndromes associated with antibodies to the Ro(SS-A) ribonuclear protein
78. Autoantibodies directed against sicca syndrome antigens in the neonatal lupus syndrome
79. Connective tissue disease, antibodies to ribonucleoprotein and congenital heart block
80. Anti-SS-A antibodies and fetal outcome in maternal systemic lupus erythematosus
81. Heterogeneity of precipitating antibodies tin polymyositis and dermatomyositis: Characterization of the Jo-1 antibody system
82. Myositis autoantibody inhibits histidyl-tRNA synthetase: A model for autoimmunity
83. His-containing antigen is recognized by the polymyositis-specific antibody anti-Jo-1
84. Rat liver histidyl-tRNA synthetase. Purification and inhibition by the myositis-specific anti-Jo-1 autoantibody
85. Anti-Jo-1 antibody: A marker for myositis with interstitial lung disease
86. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody
87. Autoantibodies against alanyl-tRNA synthetase and tRNA Ala co-exist and are associated with myositis
88. The association between Mi-2 antibodies and dermatomyositis
89. Autoantibodies specific for U1 RNA and initiator methionine tRNA
90. Human autoantibodies reactive with the signal-recognition particle
91. Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle
92. Antibodies to a nuclear/nucleolar antigen in pataients with polymyositis overlap syndromes
93. Immunolocalization and partial characterization of a nucleolar antigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes
94. Nucleolar localization of the PM-Scl antigen
95. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma
96. Autoantibodies to topoisomerase I are found in sera from scleroderma patients
97. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase
98. Scl-70 autoantibodies from scleroderma patients recognize a 95 KD protein identified as DNA topoisomerase I
99. Scl-70 antibody—A specific marker of systemic sclerosis
100. Autoantibody to RNA polymerase I in scleroderma sera
101. Monoclonal autoantibody from NZB/NZW F1 mouse and some human scleroderma sera target a Mr 34,000 nucleolar protein of the U3-ribonucleoprotein particle
102. G-dimethylarginine
103. Fibrillarin: A new protein of the nucleolus identified by autoimmune sera
104. Autoimmune response directed against conserved determinants of nuclear envelope proteins in a patient with linear scleroderma
105. Site-specific polyadenylation in a cell-free reaction
106. Are U4 small nuclear ribonucleoproteins involved in polyadenylation?
107. DNA topoisomerases—Enzymes that catalyse the breaking and rejoining of DNA
108. A subset of yeast snRNAs contains functional binding sites for the highly conserved Sm antigen
109. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active in ribosomal DNA
110. intranuclear compartmentalization of DNA-dependent RNA polymerases: Association of RNA polymerase I with nucleolar organizing chromosomes
111. Autoantibody to proliferating cell nuclear antigen neutralizes the activity of the auxiliary protein for DNA polymerase delta
112. Human autoantibody-reactive epitopes of SS-B/La are highly conserved in comparison with epitopes recognized by murine monoclonal antibodies
113. The basis for the immunoregulatory role of macrophage and other accessory cells
114. Current concepts Immunology Idiotypes and idiotypic networks